[ad_1]
(CercleFinance.com) – Sanofi announces that it will present new data on Beyfortus (nirsevimab) during IDWeek 2024, demonstrating the effectiveness and safety of its treatment against respiratory syncytial virus (RSV) in infants.
According to Thomas Triomphe, executive vice-president of Sanofi Vaccines, ‘Beyfortus demonstrated an effectiveness of more than 80% in its first year of implementation.’
Several independent studies, notably in Chile and Spain, will confirm these results during the event, assures the laboratory.
[ad_2]
Source link -86